To ensure generative AI competency and use becomes pervasive across the enterprise, CISOs and their colleagues must establish ...
Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of IgA nephropathy (IgAN) portfolioC3 glomerulopathy (C3G) studi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback